CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤中的 CAR-T 细胞
英文原题：Chimeric Antigen Receptor T Cells in Multiple Myeloma.
查看英文原题
Chimeric Antigen Receptor T Cells in Multiple Myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤是第二常见的血液系统恶性肿瘤，年发病率约为每10万人中8.5例。过去十年间，多发性骨髓瘤的治疗发生了革命性变化。嵌合抗原受体（CAR）T细胞疗法在这一演变中发挥了重要作用。在本综述中，我们讨论CAR-T 细胞疗法在多发性骨髓瘤中的现状，同时评估近期有望出现的几种新型疗法和靶点。
展开英文摘要原文
Multiple myeloma is the second most common hematological malignancy with an approximate incidence of up to 8.5 cases per 100,000 persons per year. Over the last decade, therapy for multiple myeloma has undergone a revolutionary change. Chimeric antigen receptor (CAR) T-cell therapy has played a major role in this evolution. In this review, we discuss the existing state of CAR T-cell therapy in myeloma while evaluating several newer therapies and targets expected in the near future.
论文信息
- 作者
- Shah P、Sperling AS
- 单位
- Department of Hematology, Dartmouth Cancer Center, 1 Medical Center Drive, Lebanon, NH 03750, USA; Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA. Electronic address: Parth_Shah@DFCI.HARVARD.EDU.United States
- 文献类型
- 综述 · 美国 NIH 资助研究 · 非美国政府资助研究 · 美国政府（非公共卫生署）资助研究
- 期刊
- Hematology/oncology clinics of North America2023 Dec
- 原文标识
- PubMed 37563077 · DOI 10.1016/j.hoc.2023.05.008